title: [Acantholytic dermatosis in patients treated by vemurafenib: 2 cases].
abstract: BACKGROUND
  Acantholytic dyskeratosis under BRAF inhibitors are dermatological diseases rarely reported to date.
  
  
  METHODS
  We report 2 cases of acantholytic dyskeratosis, reaching the trunk and the seborrheic zones, not itchy, appeared one month after the introduction of vemurafenib. The histological analysis was typical of a "Grover-like rash" for the 2 patients.
  
  
  CONCLUSIONS
  The appearance of acantholytic dyskeratosis under vemurafenib, a BRAF inhibitor, seems related with a paradoxical activation of the MAP-kinases pathway and with a growth acceleration of lesions in which RAS mutations of keratinocytes. Theses dermatoses seem also to occur with dabrafenib.
  
  
  CONCLUSIONS
  The patients treated by BRAF inhibitors (vemurafenib and dabrafenib) can present acantholytic dyskeratosis. The arisen of this mild dermatosis does not question, of course, the continuation of the treatment. These cutaneous manifestations can be managed with emollients.
authors.affiliation: Clinique de dermatologie et photobiologie, hôpital Nord, CHU de Grenoble, Cs 10217, boulevard de la-Chantourne-La-Tronche, 38043 Grenoble cedex 9, France. Electronic address: msabatiervincent@chu-grenoble.fr.
authors.forename: M
authors.initials: M
authors.lastname: Sabatier-Vincent
authors.affiliation: Clinique de dermatologie et photobiologie, hôpital Nord, CHU de Grenoble, Cs 10217, boulevard de la-Chantourne-La-Tronche, 38043 Grenoble cedex 9, France.
authors.forename: J
authors.initials: J
authors.lastname: Charles
authors.affiliation: Département d'anatomie pathologique, CHU de Grenoble, Cs 10217, 38043 Grenoble cedex 9, France.
authors.forename: N
authors.initials: N
authors.lastname: Pinel
authors.affiliation: Clinique de dermatologie et photobiologie, hôpital Nord, CHU de Grenoble, Cs 10217, boulevard de la-Chantourne-La-Tronche, 38043 Grenoble cedex 9, France.
authors.forename: I
authors.initials: I
authors.lastname: Challende
authors.affiliation: Clinique de dermatologie et photobiologie, hôpital Nord, CHU de Grenoble, Cs 10217, boulevard de la-Chantourne-La-Tronche, 38043 Grenoble cedex 9, France.
authors.forename: A
authors.initials: A
authors.lastname: Claeys
authors.affiliation: Clinique de dermatologie et photobiologie, hôpital Nord, CHU de Grenoble, Cs 10217, boulevard de la-Chantourne-La-Tronche, 38043 Grenoble cedex 9, France.
authors.forename: M-T
authors.initials: MT
authors.lastname: Leccia
mesh_terms: D000051:Acantholysis / Q000139:chemically induced*; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D003875:Drug Eruptions / Q000209:etiology*; D005076:Exanthema / Q000139:chemically induced; D005260:Female; D006801:Humans; D007057:Ichthyosis / Q000139:chemically induced*; D007093:Imidazoles / Q000009:adverse effects; D007211:Indoles / Q000009:adverse effects*; D020935:MAP Kinase Signaling System / Q000187:drug effects; D008297:Male; D008545:Melanoma / Q000188:drug therapy / Q000235:genetics / Q000556:secondary; D008875:Middle Aged; D009154:Mutation / Q000187:drug effects / Q000235:genetics; D010091:Oximes / Q000009:adverse effects; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors* / Q000235:genetics; D013449:Sulfonamides / Q000009:adverse effects*; D000077484:Vemurafenib; D018631:ras Proteins / Q000187:drug effects / Q000235:genetics
chemical_list: D000970:Antineoplastic Agents; D007093:Imidazoles; D007211:Indoles; D010091:Oximes; D013449:Sulfonamides; D000077484:Vemurafenib; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf; D018631:ras Proteins; C561627:dabrafenib
keywords: Acantholytic dyskeratosis; Dermatose acantholytique; Drug adverse effects; Effets secondaires des médicaments; Grover; Melanoma; Mélanome; Vemurafenib; Vémurafénib